Fate Therapeutics (FATE) Assets Average (2013 - 2026)

Fate Therapeutics' Assets Average history runs 14 years deep, the most recent figure standing at $301.9 million for Q1 2026.

• Quarterly Assets Average fell 28.06% year-over-year to $301.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301.9 million (down 28.06% YoY) and the FY2025 annual result came in at $379.8 million, down 19.78% from the prior year.
• Assets Average was $301.9 million for Q1 2026 at Fate Therapeutics, down from $331.3 million in the prior quarter.
• Across five years, Assets Average topped out at $889.9 million in Q1 2022 and bottomed at $301.9 million in Q1 2026.
• A 5-year average of $556.2 million and a median of $538.1 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average rose 6.68% — and 2025, when it sank 30.13%.
• Fate Therapeutics' Assets Average stood at $727.5 million in 2022, then retreated by 27.83% to $525.0 million in 2023, then declined by 10.89% to $467.8 million in 2024, then retreated by 29.18% to $331.3 million in 2025, then retreated by 8.87% to $301.9 million in 2026.
• Business Quant data shows FATE's Assets Average at $301.9 million in Q1 2026, $331.3 million in Q4 2025, and $357.7 million in Q3 2025.